Calliditas Therapeutics AB (publ) (CALT) News Today $40.00 0.00 (0.00%) (As of 12/17/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period 16,117 Shares in Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Bought by Crossmark Global Holdings Inc.Crossmark Global Holdings Inc. bought a new stake in Calliditas Therapeutics AB (publ) (NASDAQ:CALT - Free Report) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 16,117 shares of the company's stock, valued at approximatelyNovember 16, 2024 | marketbeat.comCalliditas Therapeutics to Present Four Abstracts at American Society of Nephrology (ASN) Kidney Week 2024October 17, 2024 | tmcnet.comCalliditas Therapeutics (NASDAQ:CALT) Stock Quotes, Forecast and News SummaryOctober 4, 2024 | benzinga.comCalliditas Therapeutics AB (publ) (NASDAQ:CALT) Reaches New 52-Week High at $43.00Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Reaches New 1-Year High at $43.00September 20, 2024 | marketbeat.comDelisting of Calliditas Therapeutics AB (publ) from Nasdaq StockholmSeptember 16, 2024 | prnewswire.comCalliditas Therapeutics AB (publ) (NASDAQ:CALT) Short Interest Down 60.7% in AugustCalliditas Therapeutics AB (publ) (NASDAQ:CALT - Get Free Report) saw a large decline in short interest in the month of August. As of August 31st, there was short interest totalling 3,500 shares, a decline of 60.7% from the August 15th total of 8,900 shares. Based on an average daily volume of 9,500 shares, the days-to-cover ratio is currently 0.4 days.September 13, 2024 | marketbeat.comCalliditas Therapeutics AB (publ) (NASDAQ:CALT) Sets New 12-Month High at $41.91Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Hits New 1-Year High at $41.91September 3, 2024 | marketbeat.comNotice of extraordinary meeting of Calliditas Therapeutics AB (publ)September 3, 2024 | prnewswire.comCalliditas Therapeutics takes certain corporate actions following announcement by Asahi KaseiSeptember 3, 2024 | prnewswire.comCalliditas Therapeutics AB (publ) (NASDAQ:CALT) Sees Large Growth in Short InterestCalliditas Therapeutics AB (publ) (NASDAQ:CALT - Get Free Report) saw a large increase in short interest in August. As of August 15th, there was short interest totalling 8,900 shares, an increase of 39.1% from the July 31st total of 6,400 shares. Based on an average daily volume of 15,700 shares, the short-interest ratio is presently 0.6 days.August 31, 2024 | marketbeat.comCalliditas Therapeutics AB (publ) (NASDAQ:CALT) Sees Large Volume IncreaseCalliditas Therapeutics AB (publ) (NASDAQ:CALT) Sees Strong Trading VolumeAugust 27, 2024 | marketbeat.comCalliditas Therapeutics AB (publ) (NASDAQ:CALT) Sees Unusually-High Trading VolumeCalliditas Therapeutics AB (publ) (NASDAQ:CALT) Sees Unusually-High Trading VolumeAugust 15, 2024 | marketbeat.comShort Interest in Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Drops By 23.8%Calliditas Therapeutics AB (publ) (NASDAQ:CALT - Get Free Report) was the recipient of a large decline in short interest in the month of July. As of July 31st, there was short interest totalling 6,400 shares, a decline of 23.8% from the July 15th total of 8,400 shares. Based on an average daily volume of 13,700 shares, the days-to-cover ratio is currently 0.5 days.August 15, 2024 | marketbeat.comCalliditas Therapeutics AB (publ) (NASDAQ:CALT) Q2 2024 Earnings Call TranscriptAugust 14, 2024 | msn.comCalliditas Therapeutics AB (publ) (NASDAQ:CALT) Issues Quarterly Earnings ResultsCalliditas Therapeutics AB (publ) (NASDAQ:CALT - Get Free Report) issued its quarterly earnings data on Tuesday. The company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.25) by $0.09. Calliditas Therapeutics AB (publ) had a negative return on equity of 160.87% and a negative net margin of 40.19%. The business had revenue of $52.36 million during the quarter, compared to analyst estimates of $42.89 million. During the same period in the prior year, the company posted ($0.33) EPS.August 14, 2024 | marketbeat.comCalliditas Therapeutics AB (publ) (NASDAQ:CALT) Receives Consensus Rating of "Hold" from BrokeragesShares of Calliditas Therapeutics AB (publ) (NASDAQ:CALT - Get Free Report) have received a consensus rating of "Hold" from the six ratings firms that are currently covering the firm, MarketBeat reports. Six investment analysts have rated the stock with a hold recommendation. The average twelve-moAugust 14, 2024 | marketbeat.comCalliditas Therapeutics AB (publ) (CALT) Q2 2024 Earnings Call TranscriptAugust 13, 2024 | seekingalpha.comCalliditas Therapeutics (spons ADRs) earnings: here's what Wall Street expectsAugust 13, 2024 | markets.businessinsider.comCalliditas Interim Report January to June 2024August 13, 2024 | prnewswire.comLC8.SG,0P0001K80V,0 (LC8.SG)August 12, 2024 | ca.finance.yahoo.comCalliditas Therapeutics AB (publ) (CALT) Set to Announce Earnings on TuesdayCalliditas Therapeutics AB (publ) (NASDAQ:CALT) will be releasing earnings before the market opens on Tuesday, August 13, Zacks reports. (Register for Conference Call at na)August 6, 2024 | marketbeat.comCalliditas Therapeutics AB (publ) (NASDAQ:CALT) Trading Up 1.2%Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Trading 1.2% HigherAugust 5, 2024 | marketbeat.comCalliditas Therapeutics to Attend 2024 Women in Nephrology (WIN) Leadership ConferenceAugust 1, 2024 | markets.businessinsider.comCalliditas Therapeutics AB (publ) (NASDAQ:CALT) Sees Strong Trading VolumeCalliditas Therapeutics AB (publ) (NASDAQ:CALT) Sees Large Volume IncreaseAugust 1, 2024 | marketbeat.comNumber of shares and votes in Calliditas TherapeuticsJuly 31, 2024 | prnewswire.comSTOCKHOLDER ALERT: The M&A Class Action Firm Is Investigating the Merger and its Tender Offer for Calliditas Therapeutics AB – CALTJuly 27, 2024 | globenewswire.comSTOCKHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of the Merger and its Tender Offer, Expiring August 30, 2024, for shares of Calliditas Therapeutics AB - CALTJuly 26, 2024 | prnewswire.comCALT Aug 2024 40.000 call (CALT240816C00040000)July 26, 2024 | finance.yahoo.comCalliditas announces positive TRANSFORM Phase 2b topline data in primary biliary cholangitisJuly 26, 2024 | prnewswire.comCalliditas Therapeutics AB (publ) (LC8A.F)July 20, 2024 | nz.finance.yahoo.comCalliditas Therapeutics AB (publ) (NASDAQ:CALT) Given Consensus Rating of "Hold" by AnalystsShares of Calliditas Therapeutics AB (publ) (NASDAQ:CALT - Get Free Report) have been assigned a consensus rating of "Hold" from the six research firms that are currently covering the company, MarketBeat reports. Six analysts have rated the stock with a hold rating. The average 1-year price objectJuly 20, 2024 | marketbeat.comCalliditas Therapeutics AB (publ) (NASDAQ:CALT) Short Interest Up 13.4% in JuneCalliditas Therapeutics AB (publ) (NASDAQ:CALT - Get Free Report) saw a significant increase in short interest in the month of June. As of June 30th, there was short interest totalling 9,300 shares, an increase of 13.4% from the June 15th total of 8,200 shares. Based on an average trading volume of 13,800 shares, the days-to-cover ratio is currently 0.7 days.July 15, 2024 | marketbeat.comLaunch of Phase 3 clinical trial with Nefecon in JapanJuly 4, 2024 | prnewswire.comCalliditas Therapeutics AB (publ) (NASDAQ:CALT) Given Average Recommendation of "Hold" by AnalystsShares of Calliditas Therapeutics AB (publ) (NASDAQ:CALT - Get Free Report) have been given an average recommendation of "Hold" by the six brokerages that are presently covering the firm, MarketBeat Ratings reports. Six equities research analysts have rated the stock with a hold recommendation. ThJune 25, 2024 | marketbeat.comCalliditas provides setanaxib patent updateJune 18, 2024 | prnewswire.comBulletin from the annual general meeting of Calliditas Therapeutics AB (publ)June 17, 2024 | prnewswire.comShort Interest in Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Declines By 16.3%Calliditas Therapeutics AB (publ) (NASDAQ:CALT - Get Free Report) was the target of a large decline in short interest in May. As of May 31st, there was short interest totalling 8,200 shares, a decline of 16.3% from the May 15th total of 9,800 shares. Based on an average daily trading volume, of 12,200 shares, the short-interest ratio is presently 0.7 days.June 15, 2024 | marketbeat.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AKLI, CALT, SGE on Behalf of ShareholdersJune 7, 2024 | globenewswire.comSTOCKHOLDER INVESTIGATION: The M&A Class Action Firm Announces An Investigation of the Merger and its Tender Offer, Expiring July 18, 2024, for shares of Calliditas Therapeutics AB – CALTJune 5, 2024 | globenewswire.comSTOCKHOLDER INVESTIGATION: The M&A Class Action Firm Announces An Investigation of the Merger and its Tender Offer, Expiring July 18, 2024, for shares of Calliditas Therapeutics AB - CALTJune 4, 2024 | prnewswire.comCalliditas Therapeutics AB (publ) (NASDAQ:CALT) Hits New 52-Week High at $40.49Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Hits New 12-Month High at $40.49June 4, 2024 | marketbeat.comShort Interest in Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Rises By 12.6%Calliditas Therapeutics AB (publ) (NASDAQ:CALT - Get Free Report) was the target of a large growth in short interest in May. As of May 15th, there was short interest totalling 9,800 shares, a growth of 12.6% from the April 30th total of 8,700 shares. Based on an average daily volume of 5,500 shares, the short-interest ratio is currently 1.8 days.June 1, 2024 | marketbeat.comCalliditas Therapeutics AB (publ) (NASDAQ:CALT) Given Consensus Recommendation of "Hold" by BrokeragesCalliditas Therapeutics AB (publ) (NASDAQ:CALT - Get Free Report) has received an average rating of "Hold" from the six brokerages that are presently covering the stock, Marketbeat Ratings reports. Six investment analysts have rated the stock with a hold recommendation. The average 12-month priceMay 31, 2024 | marketbeat.comCalliditas Therapeutics AB (publ) (NASDAQ:CALT) Stock Rating Reaffirmed by CitigroupCitigroup reaffirmed a "neutral" rating and issued a $39.00 price target on shares of Calliditas Therapeutics AB (publ) in a research note on Friday.May 31, 2024 | marketbeat.comCalliditas partner STADA receives positive CHMP opinion recommending full approval for Kinpeygo® for the treatment of IgA nephropathyMay 30, 2024 | prnewswire.comCalliditas Therapeutics AB (publ) (NASDAQ:CALT) Shares Gap Up to $37.94Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Shares Gap Up to $37.94May 30, 2024 | marketbeat.comCalliditas Therapeutics AB (publ) (NASDAQ:CALT) Downgraded by Lifesci CapitalLifesci Capital downgraded Calliditas Therapeutics AB (publ) from a "strong-buy" rating to a "hold" rating in a report on Tuesday.May 30, 2024 | marketbeat.comSwedish Exchange Growth Leaders: 3 Companies With Significant Insider OwnershipMay 28, 2024 | finance.yahoo.comMaintaining Hold on Calliditas: Assessing Acquisition Fairness Amid Evolving IgAN Market DynamicsMay 28, 2024 | markets.businessinsider.comJefferies Financial Group Reiterates Hold Rating for Calliditas Therapeutics AB (publ) (NASDAQ:CALT)Jefferies Financial Group reissued a "hold" rating and set a $39.00 target price (down from $58.00) on shares of Calliditas Therapeutics AB (publ) in a report on Tuesday.May 28, 2024 | marketbeat.com Get Calliditas Therapeutics AB (publ) News Delivered to You Automatically Sign up to receive the latest news and ratings for CALT and its competitors with MarketBeat's FREE daily newsletter. Email Address Do this Before Elon’s Reveal on January 22nd (Ad)Elon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but designed to power a $9 trillion AI revolution. And I’ve identified a little-known supplier Elon is depending on to make it all happen. I urge you to watch this video now. CALT Media Mentions By Week CALT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CALT News Sentiment▼0.000.65▲Average Medical News Sentiment CALT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CALT Articles This Week▼02▲CALT Articles Average Week Get Calliditas Therapeutics AB (publ) News Delivered to You Automatically Sign up to receive the latest news and ratings for CALT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Arcellx News ADMA Biologics News Ultragenyx Pharmaceutical News Apellis Pharmaceuticals News Biohaven News Immunovant News Avidity Biosciences News Scholar Rock News Organon & Co. News PTC Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CALT) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | Sponsored2025’s #1 Trump TradeAll the Energy You Need to Power Your Entire Life... Could Fit Inside This Single Soda Can. Three Companies...The Oxford Club | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredHealthcare Takes A Big Step Forward With The Help of A.I.To date, we've seen baseline AI models lay the groundwork. Tools like ChatGPT are useful, but they are still s...Wall Street Star | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | Sponsored50-year Wall Street legend: “Sell this tech stock NOW”Something very strange is happening to U.S. stocks following President Trump's victory... And this could s...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Calliditas Therapeutics AB (publ) Please log in to your account or sign up in order to add this asset to your watchlist. Share Calliditas Therapeutics AB (publ) With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CALT Stock Alerts